Article
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
The Lancet. Oncology - 1 Aug 2011
Zhou Caicun, Wu Yi-Long, Chen Gongyan, Feng Jifeng, Liu Xiao-Qing, Wang Changli, Zhang Shucai, Wang Jie, Zhou Songwen, Ren Shengxiang, Lu Shun, Zhang Li, Hu Chengping, Hu Chunhong, Luo Yi, Chen Lei, Ye Ming, Huang Jianan, Zhi Xiuyi, Zhang Yiping, Xiu Qingyu, Ma Jun, Zhang Li, You Changxuan
Abstract excerpt
BACKGROUND: Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. METHODS: We undertook an open-label, randomised, phase 3 trial at 22...
Topics
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Carcinoma, Non-Small-Cell Lung
- China
- Deoxycytidine